Biperiden

Research use only, not for human use.

Biperiden (KL 373) is a centrally-acting antiparkinsonian agent that functions as a selective central M1 cholinoreceptors blocker.

Biperiden (KL 373) is a centrally-acting antiparkinsonian agent that functions as a selective central M1 cholinoreceptors blocker.Parkinson Disease Approved.

Biperiden (29.6 μg/ml, 72 hours) can significantly induce apoptosis and inhibit proliferation at high doses in human pancreatic ductal adenocarcinoma cells.Cell Proliferation Assay Cell Line:Panc-1, Panc-2 and BxPC3 human pancreatic ductal adenocarcinoma cells Concentration:29.6 μg/mL Incubation Time:72 hours Result:Inhibited cell proliferation at 72 hours significantly by reducing nuclear c-Rel translocation.

Biperiden (intraperitoneal injection, 10 mg/kg, everyday, 3 weeks) reduces tumor size by 83% in subcutaneous xenograft mouse using Panc-1 human pancreatic ductal adenocarcinoma cells. Biperiden (intraperitoneal injection, 8 mg/kg, every 8 hours, 10 days) can reduce frequency of spontaneous seizures and extracellular hippocampal glutamate levels while cause a long-term decrease in hippocampal excitability. Animal Model:Subcutaneous xenograft mouse using Panc-1 human pancreatic ductal adenocarcinoma cells Dosage:10 mg/kg Administration:Intraperitoneal injection; everyday; 3 weeks Result:Tumor size reduced by 83%.Animal Model:Male Wistar rats (200-250 g)Dosage:8 mg/kg Administration:Intraperitoneal injection; every 8 hours; 10 days Result:Reduced late seizures by about three times with no affecting emotional memory damage.

KL 373

GPCR/G Protein

mAChR

mAChR

Neurological Disease

Parkinson Disease

514-65-8

311.4611

C21H29NO

>98% (HPLC)

10 mM in DMSO

OC(C1=CC=CC=C1)(C2CC3C=CC2C3)CCN4CCCCC4

1-Piperidinepropanol, α-bicyclo[2.2.1]hept-5-en-2-yl-α-phenyl-

(-20℃)

With Ice Pack

≥ 2 years